BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

206 related articles for article (PubMed ID: 30898625)

  • 1. Disappearance of a myoma after pregnancy in a 38 years old patient, treated by ulipristal acetate without success before getting pregnant.
    Pécout M; Cosson M; Collinet P; Rubod C; Giraudet G
    J Gynecol Obstet Hum Reprod; 2019 Nov; 48(9):781-783. PubMed ID: 30898625
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Uterine fibroid management: from the present to the future.
    Donnez J; Dolmans MM
    Hum Reprod Update; 2016 Nov; 22(6):665-686. PubMed ID: 27466209
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Place of ulipristal acetate in the management of uterine fibroids: Preoperative treatment or sequential treatment?
    Pourcelot AG; Capmas P; Fernandez H
    J Gynecol Obstet Hum Reprod; 2017 Mar; 46(3):249-254. PubMed ID: 28403922
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The management of uterine leiomyomas.
    Vilos GA; Allaire C; Laberge PY; Leyland N;
    J Obstet Gynaecol Can; 2015 Feb; 37(2):157-178. PubMed ID: 25767949
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Ulipristal acetate vs gonadotropin-releasing hormone agonists prior to laparoscopic myomectomy (MYOMEX trial): Short-term results of a double-blind randomized controlled trial.
    de Milliano I; Huirne JAF; Thurkow AL; Radder C; Bongers MY; van Vliet H; van de Lande J; van de Ven PM; Hehenkamp WJK
    Acta Obstet Gynecol Scand; 2020 Jan; 99(1):89-98. PubMed ID: 31468503
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The management of uterine fibroids in women with otherwise unexplained infertility.
    Carranza-Mamane B; Havelock J; Hemmings R; ;
    J Obstet Gynaecol Can; 2015 Mar; 37(3):277-285. PubMed ID: 26001875
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Selective progesterone receptor modulator (ulipristal acetate--a new option in the pharmacological treatment of uterine fibroids in women].
    Szamatowicz M; Kotarski J
    Ginekol Pol; 2013 Mar; 84(3):219-22. PubMed ID: 23700851
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Treatment Choices in a National Cohort of Canadian Women With Symptomatic Uterine Fibroids.
    Strand T; Kives S; Leyland N; Ashkenas J; Janiszewski P; Thiel J
    J Obstet Gynaecol Can; 2020 Dec; 42(12):1475-1482.e2. PubMed ID: 33046429
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Preoperative Treatment with Ulipristal Acetate before Outpatient Hysteroscopic Myomectomy.
    Ferrero S; Scala C; Vellone VG; Paudice M; Vitale SG; Cianci A; Barra F
    Gynecol Obstet Invest; 2020; 85(2):178-183. PubMed ID: 31940645
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [LAPAROSCOPIC MYOMECTOMY AFTER ULIPRISTAL ACFTATF TRFATMFMT.].
    Blagovest B; Magunska N
    Akush Ginekol (Sofiia); 2016; 55(5):29-31. PubMed ID: 29790712
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Guideline No. 389-Medical Management of Symptomatic Uterine Leiomyomas - An Addendum.
    Laberge PY; Murji A; Vilos GA; Allaire C; Leyland N; Singh SS
    J Obstet Gynaecol Can; 2019 Oct; 41(10):1521-1524. PubMed ID: 31548041
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Individualized vaginal bleeding experience of women with uterine fibroids in the PEARL I randomized controlled trial comparing the effects of ulipristal acetate or placebo.
    Barlow DH; Lumsden MA; Fauser BC; Terrill P; Bestel E
    Hum Reprod; 2014 Mar; 29(3):480-9. PubMed ID: 24457604
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacokinetic drug evaluation of ulipristal acetate for the treatment of uterine fibroids.
    Ferrero S; Vellone VG; Barra F
    Expert Opin Drug Metab Toxicol; 2018 Jan; 14(1):107-116. PubMed ID: 29250979
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Therapeutic management of uterine fibroid tumors: updated French guidelines.
    Marret H; Fritel X; Ouldamer L; Bendifallah S; Brun JL; De Jesus I; Derrien J; Giraudet G; Kahn V; Koskas M; Legendre G; Lucot JP; Niro J; Panel P; Pelage JP; Fernandez H;
    Eur J Obstet Gynecol Reprod Biol; 2012 Dec; 165(2):156-64. PubMed ID: 22939241
    [TBL] [Abstract][Full Text] [Related]  

  • 15. EMAS position statement: management of uterine fibroids.
    Pérez-López FR; Ornat L; Ceausu I; Depypere H; Erel CT; Lambrinoudaki I; Schenck-Gustafsson K; Simoncini T; Tremollieres F; Rees M;
    Maturitas; 2014 Sep; 79(1):106-16. PubMed ID: 24975954
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Ulipristal acetate for uterine fibroid-related symptoms.
    Puchar A; Luton D; Koskas M
    Drugs Today (Barc); 2015 Nov; 51(11):661-7. PubMed ID: 26744741
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Outcome of patients with uterine fibroids after 3-month ulipristal acetate therapy.
    Brun JL; Rajaonarison J; Froeliger A; Monseau-Thiburce AC; Randriamboavonjy R; Vogler A
    Eur J Obstet Gynecol Reprod Biol; 2018 Mar; 222():13-18. PubMed ID: 29328939
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Use of Ulipristal Acetate for the Management of Fibroid-Related Acute Abnormal Uterine Bleeding.
    Arendas K; Leyland NA
    J Obstet Gynaecol Can; 2016 Jan; 38(1):80-3. PubMed ID: 26872761
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Fibroid management in premenopausal women.
    Donnez J; Courtoy GE; Dolmans MM
    Climacteric; 2019 Feb; 22(1):27-33. PubMed ID: 30601065
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Economic impact of ulipristal acetate on surgical procedures for uterine fibroids in France.
    Fernandez H; Jourdain O; Villefranque V; Lehmann M; Lafuma A; Trancart M
    BMJ Open; 2017 Sep; 7(9):e015571. PubMed ID: 28871011
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.